ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Omega Fix for Obesity: How the Right Fats Fight Fat

How Pomegranate May Protect Against Cancer

Trimming the spare tire: Canola oil may cut belly fat

The Onion: Cancer Fighter and Food Preserver

Safely Reduce a Common Cause of Stomach Distress

 
Print Page
Email Article

U. of Cincinnati Recruiting CFS Patients in Study of Duloxetine for Fatigue

  [ 392 votes ]   [ Discuss This Article ]
By editor • www.ProHealth.com • January 31, 2007


Previous trials in Canada, Indiana, and elsewhere have studied the pharmaceutical drug duloxetine for treatment of pain and mood in Fibromyalgia patients. Now researchers at the University of Cincinnati Women’s Health Research Program are recruiting both male and female Chronic Fatigue Syndrome patients, ages 18 to 65, to test the drug’s efficacy for reducing fatigue in CFS – with a secondary focus on pain and depression.

They point out that as many as 70 percent of FM patients also meet criteria for CFS, and because FM responds to antidepressants such as duloxetine – dual serotonin and norepinephrine reuptake inhibitors – trials of such drugs in CFS “are clearly needed.”

Study Title & Type
A Randomized, Placebo-Controlled, Double-Blind Trial of Duloxetine in the Treatment of Patients With Chronic Fatigue Syndrome. ClinicalTrials.gov Identifier: NCT00375973

Phase II, Phase III; Interventional; Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Expected Total Enrollment: 60. Expected Last Followup: December 2009

Sponsors
University of Cincinnati and Eli Lilly and Company.

Purpose
Determine the safety and efficacy of duloxetine compared with placebo for reducing fatigue in patients diagnosed with Chronic Fatigue Syndrome (CFS).

Primary Outcomes: Multidimensional Fatigue Inventory (MFI)
Secondary Outcomes: Efficacy:; Brief Pain Inventory (BPI); Hospital Anxiety and Depression Scale (HADS); Clinical Global Impression of Severity (CGI-S); Patient Global Impression of Improvement (PGI-I); Safety: Discontinuation rates; treatment-emergent adverse events; vital signs; laboratory analyses

Discussion
Patients with CFS have 2 to 4 times the rate of depression and anxiety compared with the general population. CFS is also commonly comorbid with Fibromyalgia, a disorder characterized by chronic widespread pain, tenderness, fatigue, sleep and mood disturbances. In some samples, 70 percent of patients with Fibromyalgia also meet criteria for CFS. CFS and Fibromyalgia are characterized by greater similarities than differences and may share pathophysiologic features. Like Fibromyalgia, CFS is associated with chronic pain, sleep and mood disturbances. Because Fibromyalgia responds to treatment with antidepressants, particularly the dual serotonin and norepinephrine reuptake inhibitors, including duloxetine, antidepressant trials in CFS are clearly needed.

Criteria for Inclusion
1. Female and male outpatients between 18-65 years of age.
2. Meet criteria for revised CDC definition of CFS (at least 6 months of persistent fatigue that substantially reduces the person’s level of activity). Four or more of the following symptoms must occur with fatigue in a 6-month period: impaired memory or concentration, sore throat, tender glands, aching or stiff muscles, multijoint pain, new headaches, unrefreshing sleep, and post-exertional fatigue. (Patients with medical conditions that may explain the fatigue and psychiatric disorders, including eating disorders, psychotic disorders, bipolar disorder, melancholic depression, and substance abuse within 2 years of the onset of fatigue are excluded.)
3. Provision of written informed consent for participation in the trial.
4. Educational level and degree of understanding such that the patient can communicate intelligibly with the investigator and study staff.
5. Judged to be reliable and agree to keep all appointments for clinic visits, tests, and procedures required by the protocol.

Exclusion Criteria
1. Current melancholic major depressive disorder, or a previous diagnosis of psychosis, eating disorder, or bipolar disorder.
2. History of substance abuse or dependence within the past year, excluding nicotine and caffeine.
3. A positive urine drug screen for any substance of abuse (may be retested if positive test was for a prescribed medication that was not washed out).
4. Women who are pregnant or breast feeding; women must test negative for pregnancy at Visit 1.
5. Women of childbearing potential who are not using a medically accepted means of contraceptive when engaging in sexual intercourse.
6. Patients who, in the opinion of the investigator, are treatment-refractory [resistant/difficult] or whose response is likely to be compromised by existing or future disability compensation issues.
7. Serious unstable medical illness, including cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other unstable medical or psychiatric conditions that in the opinion of the investigator would compromise participation or would likely lead to hospitalization during the duration of the study. Abnormal TSH [thyroid-stimulating hormone] concentrations (unless treatment for hypothyroidism has been stable for at least the past 3 months and the patient is clinically euthyroid [normal thyroid function]).
8. Patients who have uncontrolled narrow-angle glaucoma.
9. Patients who have acute liver injury (such as hepatitis) or severe cirrhosis (Child-Pugh Class C).
10. Patients who are judged prior to randomization to be at suicidal risk by the clinical investigator.
11. Treatment with antidepressant medication within 14 days prior to randomization with the exception of fluoxetine - which cannot be used within 30 days prior to randomization. Potential need to use a MAOI [monoamine oxidase inhibitor] during the study or within 2 weeks of discontinuation of study treatment.
12. Patients who have previously taken duloxetine.
13. Patients who are taking any excluded medications that cannot be discontinued at Visit 1.
14. Treatment within the last 30 days with a drug that has not received regulatory approval at the time of study entry.
15. Known hypersensitivity to duloxetine or any of the inactive ingredients.

Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00375973
Jennifer M Hoff, MSW, LSW. Phone: 513-475-8114
E-mail: jennifer.hoff@uc.edu
Susie G Sheridan, BS. Phone: 513-475-8115 E-mail: dana.sheridan@uc.edu

Location
Ohio Psychiatric Professional Services Inc.,
Women's Health Research Program,
Cincinnati, Ohio, 45219, United States;
Recruiting Lesley M. Arnold, MD, Principal Investigator

Principal investigator
Lesley M Arnold, MD, University of Cincinnati Women's Health Research Program




Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Optimized Curcumin Longvida® Vitamin D3 Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders
"It's Not Easy Being Green" - But It Is Healthy
Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask
Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire
Top 3 Nutrients to Detox the Liver and Soothe Digestion Top 3 Nutrients to Detox the Liver and Soothe Digestion

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map